WO2003075839A2 - Methods of inducing terminal differentiation - Google Patents

Methods of inducing terminal differentiation Download PDF

Info

Publication number
WO2003075839A2
WO2003075839A2 PCT/US2003/006451 US0306451W WO03075839A2 WO 2003075839 A2 WO2003075839 A2 WO 2003075839A2 US 0306451 W US0306451 W US 0306451W WO 03075839 A2 WO03075839 A2 WO 03075839A2
Authority
WO
WIPO (PCT)
Prior art keywords
saha
subject
hdac
pharmaceutically acceptable
composition
Prior art date
Application number
PCT/US2003/006451
Other languages
English (en)
French (fr)
Other versions
WO2003075839A3 (en
Inventor
Victoria M. Richon
Original Assignee
Aton Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003075839(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to IL16390903A priority Critical patent/IL163909A0/xx
Priority to JP2003574115A priority patent/JP4732693B2/ja
Priority to CNA038095890A priority patent/CN1720034A/zh
Priority to EP03711372A priority patent/EP1487426B1/en
Priority to NZ535578A priority patent/NZ535578A/en
Priority to MXPA04008577A priority patent/MXPA04008577A/es
Priority to AU2003213684A priority patent/AU2003213684C1/en
Application filed by Aton Pharma, Inc. filed Critical Aton Pharma, Inc.
Priority to CA 2478094 priority patent/CA2478094C/en
Priority to BR0308250A priority patent/BR0308250A/pt
Publication of WO2003075839A2 publication Critical patent/WO2003075839A2/en
Publication of WO2003075839A3 publication Critical patent/WO2003075839A3/en
Priority to IL16390904A priority patent/IL163909A/en
Priority to NO20044112A priority patent/NO329984B1/no
Priority to HK05104380A priority patent/HK1072362A1/xx
Priority to IL197582A priority patent/IL197582A/en
Priority to NO20092714A priority patent/NO332749B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
PCT/US2003/006451 2002-03-04 2003-03-04 Methods of inducing terminal differentiation WO2003075839A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NZ535578A NZ535578A (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
BR0308250A BR0308250A (pt) 2002-03-04 2003-03-04 Métodos de indução de diferenciação terminal
CA 2478094 CA2478094C (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
EP03711372A EP1487426B1 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
JP2003574115A JP4732693B2 (ja) 2002-03-04 2003-03-04 最終分化を誘導する方法
MXPA04008577A MXPA04008577A (es) 2002-03-04 2003-03-04 Metodos para inducir diferenciacion terminal.
AU2003213684A AU2003213684C1 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
IL16390903A IL163909A0 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
CNA038095890A CN1720034A (zh) 2002-03-04 2003-03-04 诱导末期分化的方法
IL16390904A IL163909A (en) 2002-03-04 2004-09-05 Pharmaceutical compositions comprising a suberoylanilide hydroxamic acid (saha) or a pharmaceutically acceptable salt or hydrate and uses of said saha or pharmaceutcally acceptable salt or hydrate thereof
NO20044112A NO329984B1 (no) 2002-03-04 2004-09-28 Sammensetning omfattende krystallinsk suberoylanilid hydroksaminsyre (SAHA) samt fremgangsmate for fremstilling derav
HK05104380A HK1072362A1 (en) 2002-03-04 2005-05-25 Methods of inducing terminal differentiation
IL197582A IL197582A (en) 2002-03-04 2009-03-12 Pharmaceutical preparations containing crystalline form of hydroxylamide of sebroylanilide (saha) and methods of making saha
NO20092714A NO332749B1 (no) 2002-03-04 2009-07-20 Anvendelse av suberoylanilidhydroksaminsyre for fremstilling av et oralt medikament til behandling av kreft

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36175902P 2002-03-04 2002-03-04
US60/361,759 2002-03-04

Publications (2)

Publication Number Publication Date
WO2003075839A2 true WO2003075839A2 (en) 2003-09-18
WO2003075839A3 WO2003075839A3 (en) 2003-12-31

Family

ID=27805074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006451 WO2003075839A2 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation

Country Status (18)

Country Link
US (7) US20040072735A1 (US20040072735A1-20040415-C00087.png)
EP (4) EP2082737B1 (US20040072735A1-20040415-C00087.png)
JP (4) JP4732693B2 (US20040072735A1-20040415-C00087.png)
KR (2) KR100892016B1 (US20040072735A1-20040415-C00087.png)
CN (3) CN101259120B (US20040072735A1-20040415-C00087.png)
AU (1) AU2003213684C1 (US20040072735A1-20040415-C00087.png)
BR (1) BR0308250A (US20040072735A1-20040415-C00087.png)
CA (3) CA2671976C (US20040072735A1-20040415-C00087.png)
ES (1) ES2532607T3 (US20040072735A1-20040415-C00087.png)
HK (1) HK1072362A1 (US20040072735A1-20040415-C00087.png)
IL (3) IL163909A0 (US20040072735A1-20040415-C00087.png)
MX (1) MXPA04008577A (US20040072735A1-20040415-C00087.png)
NO (2) NO329984B1 (US20040072735A1-20040415-C00087.png)
NZ (3) NZ550185A (US20040072735A1-20040415-C00087.png)
PL (1) PL372239A1 (US20040072735A1-20040415-C00087.png)
RU (3) RU2394022C2 (US20040072735A1-20040415-C00087.png)
WO (1) WO2003075839A2 (US20040072735A1-20040415-C00087.png)
ZA (2) ZA200407942B (US20040072735A1-20040415-C00087.png)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050076A1 (fr) * 2002-11-28 2004-06-17 Centre National De La Recherche Scientifique Cnrs Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
EP1482962A2 (en) * 2002-02-15 2004-12-08 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
EP1663194A2 (en) * 2003-08-26 2006-06-07 Aton Pharma, Inc. Method of treating cancer with hdac inhibitors
WO2006127319A2 (en) * 2005-05-20 2006-11-30 Merck & Co., Inc. Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2007030697A2 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
JP2008509075A (ja) * 2004-08-09 2008-03-27 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
EP1940379A2 (en) * 2005-09-30 2008-07-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methods for treatment of hemorrhagic shock and related disorders
EP2018366A1 (en) * 2006-05-16 2009-01-28 McGILL UNIVERSITY Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US7652069B2 (en) 2002-03-04 2010-01-26 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732490B2 (en) 2002-03-04 2010-06-08 Merck Hdac Research, Llc Methods of treating cancer
US7799803B2 (en) 2003-04-01 2010-09-21 The Trustees Of Columbia University In The City Of New York Hydroxamic acid compounds and methods of use thereof
EP2229941A1 (en) * 2005-05-20 2010-09-22 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8247562B2 (en) 2002-04-05 2012-08-21 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
CN103819364A (zh) * 2014-01-24 2014-05-28 中南大学 N-烃酰基环内酰胺衍生物的一锅合成方法
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
TW559390U (en) * 2002-08-27 2003-10-21 Molex Inc Electrical connector
WO2004082638A2 (en) * 2003-03-17 2004-09-30 Syrrx, Inc. Histone deacetylase inhibitors
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
KR20050022216A (ko) * 2003-08-25 2005-03-07 윤덕구 동결건조 즉석소면 및 그 제조방법
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006065075A1 (en) * 2004-12-14 2006-06-22 Biorunx Co. Ltd. Method to enhance the bone formation activity of bmp by runx2 acetylation
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080161355A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
KR101345002B1 (ko) * 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
JP5475235B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP2500063A1 (en) 2005-02-03 2012-09-19 TopoTarget UK Limited Combination therapy using HDAC inhibitors and melphalan for treating cancer
AU2006226861B2 (en) 2005-03-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
WO2006113606A2 (en) * 2005-04-18 2006-10-26 Johns Hopkins University Histone deacetylase inhibitors
EP1715334A1 (fr) * 2005-04-22 2006-10-25 Adamant Technologies SA Procédé utilisant un capteur électrochimique et électrodes formant ce capteur
EP3530290A1 (en) * 2005-05-05 2019-08-28 GlaxoSmithKline Intellectual Property Development Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2540204T3 (es) 2005-05-13 2015-07-09 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
JP2009514879A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
EP1942907A2 (en) * 2005-11-04 2008-07-16 Merck and Co., Inc. Methods of using saha and erlotinib for treating cancer
WO2007056135A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Method of treating cancers with saha and pemetrexed
EP1957056A2 (en) * 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
JP2009518394A (ja) * 2005-12-05 2009-05-07 アストラゼネカ・アクチエボラーグ エソメプラゾールの非塩形態の新規の製造方法
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
ES2481413T3 (es) 2006-02-14 2014-07-30 The President And Fellows Of Harvard College Inhibidores de histona desacetilasa
CA2649877A1 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
JP5497431B2 (ja) * 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
AU2007300532A1 (en) * 2006-09-28 2008-04-03 Merck Sharp & Dohme Corp. Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes
US8962825B2 (en) * 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
WO2008057456A2 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
WO2008106524A1 (en) * 2007-02-27 2008-09-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
JP2010540426A (ja) * 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
DK2231590T3 (da) * 2007-12-20 2012-07-09 Pharma Mar Sa Antitumorforbindelser
CN102083428A (zh) * 2008-03-07 2011-06-01 顶标公司 采用长时间连续输液Belinostat进行治疗的方法
JP5665740B2 (ja) 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
NZ592686A (en) 2008-10-15 2012-12-21 Generics Uk Ltd Process for the preparation of vorinostat from aniline, hydroxylamine and suberic acid starting materials
EP2362869A2 (en) 2008-11-26 2011-09-07 Generics [UK] Limited Polymorphs
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
ES2473792T3 (es) 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
JP2013508458A (ja) 2009-10-26 2013-03-07 ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド Ｆｔｓとｈｄａｃ阻害剤との組合せを用いたがん治療
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US20110195402A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Systems and methods for detecting drug use
WO2011127467A1 (en) * 2010-04-09 2011-10-13 Companion Diagnostics, Inc. Devices, systems, and methods for biomarker stabilization
WO2011140375A1 (en) 2010-05-05 2011-11-10 Diliberti Charles E Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20130227717A1 (en) * 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
US20120164674A1 (en) * 2010-10-28 2012-06-28 Selinfreund Richard H Devices and washes for biomarker stabilization
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
CN102793693A (zh) * 2012-09-07 2012-11-28 天津医科大学 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN105307683A (zh) 2013-03-14 2016-02-03 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
RU2017127597A (ru) 2015-01-23 2019-02-25 Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен Применение короткоцепочечных жирных кислот для профилактики рака
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
CN105055386A (zh) * 2015-08-12 2015-11-18 天津医科大学总医院 伏立诺他用于制备免疫调节药物的应用
CN106187818B (zh) * 2016-06-27 2017-12-08 刘美新 一种制备抗癌药物伏立诺他的方法
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
TW202126643A (zh) 2019-09-27 2021-07-16 日商武田藥品工業股份有限公司 雜環化合物
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
WO1998040080A1 (en) 1997-03-11 1998-09-17 Bar-Ilan University Oxyalkylene phosphate compounds and uses thereof
WO2000021979A2 (en) 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide and their use as histone deacetylase inhibitor
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
WO2001001871A1 (en) 1999-07-02 2001-01-11 Smith & Nephew, Inc. Cannula with coupling interface
WO2001018171A2 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA622801A (en) 1961-06-27 L. Clark Robert Substituted benzimidazolones
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
JPS61251649A (ja) * 1985-04-05 1986-11-08 Mitsubishi Petrochem Co Ltd ジカルボン酸ジアニリドの製造法
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
JPH11514857A (ja) 1995-09-20 1999-12-21 メルク エンド カンパニー インコーポレーテッド 抗原虫剤の標的としてのヒストンデアセチラーゼ
US6239178B1 (en) * 1996-05-17 2001-05-29 George Dimelow Alexander Lord Method of treating mammals
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
JPH10262694A (ja) 1997-03-28 1998-10-06 Sumitomo Forestry Co Ltd Ｂ細胞性リンパ腫の骨髄転移検査法
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
BR9908214A (pt) 1998-01-30 2000-11-28 Biogen Inc Tratamento para linfomas foliculares utilizando inibidores da via da linfotoxina (lt)
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
PL348673A1 (en) * 1998-09-25 2002-06-03 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6533803B2 (en) * 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1532244A4 (en) * 2001-06-14 2005-12-14 Bristol Myers Squibb Co NEW HISTONIC HUMAN DEACETYLASES
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
EP2082737B1 (en) 2002-03-04 2014-12-31 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
EP1663194B1 (en) * 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
WO2005023179A2 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
CA2617623A1 (en) * 2005-08-18 2007-02-22 Victoria M. Richon Combination methods of saha and targretin for treating cancer
EP1942907A2 (en) * 2005-11-04 2008-07-16 Merck and Co., Inc. Methods of using saha and erlotinib for treating cancer
JP2009514879A (ja) 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
WO2007056135A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Method of treating cancers with saha and pemetrexed

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5773474A (en) 1988-11-14 1998-06-30 The Trustees Of Columbia University In The City Of New York And Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5932616A (en) 1991-10-04 1999-08-03 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
WO1998040080A1 (en) 1997-03-11 1998-09-17 Bar-Ilan University Oxyalkylene phosphate compounds and uses thereof
WO2000021979A2 (en) 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide and their use as histone deacetylase inhibitor
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
WO2001001871A1 (en) 1999-07-02 2001-01-11 Smith & Nephew, Inc. Cannula with coupling interface
WO2001018171A2 (en) 1999-09-08 2001-03-15 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US6511990B1 (en) 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CURTIN M., CURRENT PATENT STATUS OF HISTONE DEACETYLASE INHIBITORS EXPERT OPIN. THER. PATENTS, vol. 12, no. 9, 2002, pages 1375 - 1384
FURAMAI R. ET AL., PNAS USA, vol. 98, no. 1, 2001, pages 87 - 92
KOMATSU, Y. ET AL., CANCER RES., vol. 61, no. 11, 2001, pages 4459 - 4466
LEE, B.I. ET AL., CANCER RES., vol. 61, no. 3, pages 931 - 934
O'CONNO; OWEN ET AL., BIOSIS
SAITO, A. ET AL., PNAS USA, vol. 96, 1999, pages 4592 - 4597
See also references of EP1487426A4
STOWELL; JOHN C. ET AL.: "The Synthesis of N-Hydroxy-N'-phenyloctanediamide and its Inhibitory effect on Proliferation of AXC Rat Prostate Cancer Cells", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 8, 1995, pages 1411 - 13
SU, G.H. ET AL., CANCER RES., vol. 60, 2000, pages 3137 - 3142
SUZUKI, T. ET AL., J. MED. CHEM., vol. 42, no. 15, 1999, pages 3001 - 3003
YOSHIDA ET AL., J. BIOL. CHEM, vol. 265, 1990, pages 17174 - 17179
YOSHIDA, M. ET AL., BIOASSAYS, vol. 17, 1995, pages 423 - 430

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482962A2 (en) * 2002-02-15 2004-12-08 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
US7732490B2 (en) 2002-03-04 2010-06-08 Merck Hdac Research, Llc Methods of treating cancer
US7652069B2 (en) 2002-03-04 2010-01-26 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US8101663B2 (en) 2002-03-04 2012-01-24 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US8067472B2 (en) 2002-03-04 2011-11-29 Merck Hdac Research, Llc Methods of treating Hodgkin's and non-Hodgkin's lymphoma
US7851509B2 (en) 2002-03-04 2010-12-14 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7847122B2 (en) 2002-03-04 2010-12-07 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US8247562B2 (en) 2002-04-05 2012-08-21 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
WO2004050076A1 (fr) * 2002-11-28 2004-06-17 Centre National De La Recherche Scientifique Cnrs Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
US7799803B2 (en) 2003-04-01 2010-09-21 The Trustees Of Columbia University In The City Of New York Hydroxamic acid compounds and methods of use thereof
EP1663194A4 (en) * 2003-08-26 2007-09-19 Aton Pharma Inc METHOD OF TREATING CANCER WITH HDAC INHIBITORS
EP2201947A3 (en) * 2003-08-26 2010-08-11 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
EP1663194A2 (en) * 2003-08-26 2006-06-07 Aton Pharma, Inc. Method of treating cancer with hdac inhibitors
JP2008509075A (ja) * 2004-08-09 2008-03-27 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
JP2008519081A (ja) * 2005-05-20 2008-06-05 メルク エンド カムパニー インコーポレーテッド スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
WO2006127319A2 (en) * 2005-05-20 2006-11-30 Merck & Co., Inc. Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2006249440C1 (en) * 2005-05-20 2009-08-13 Merck Sharp & Dohme Llc Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2006249440B2 (en) * 2005-05-20 2009-03-12 Merck Sharp & Dohme Llc Formulations of suberoylanilide hydroxamic acid and methods for producing same
KR100884500B1 (ko) * 2005-05-20 2009-02-20 머크 앤드 캄파니 인코포레이티드 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법
CN101080223B (zh) * 2005-05-20 2015-02-11 默沙东公司 辛二酰苯胺异羟肟酸制剂及其制备方法
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
US8450372B2 (en) 2005-05-20 2013-05-28 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8288440B2 (en) 2005-05-20 2012-10-16 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2006127321A2 (en) * 2005-05-20 2006-11-30 Merck & Co., Inc. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8093295B2 (en) 2005-05-20 2012-01-10 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing the same
EP2229941A1 (en) * 2005-05-20 2010-09-22 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
KR100993135B1 (ko) 2005-05-20 2010-11-10 머크 샤프 앤드 돔 코포레이션 수베로일아닐리드 하이드록삼산의 제형 및 이의 제조방법
WO2006127319A3 (en) * 2005-05-20 2007-03-29 Merck & Co Inc Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2006127321A3 (en) * 2005-05-20 2007-03-22 Merck & Co Inc Formulations of suberoylanilide hydroxamic acid and methods for producing same
EP2292221A3 (en) * 2005-05-20 2011-08-10 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201650B2 (en) * 2005-05-20 2011-09-15 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
AU2009201652B2 (en) * 2005-05-20 2011-10-06 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
JP2011251985A (ja) * 2005-05-20 2011-12-15 Merck Sharp & Dohme Corp スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007030697A2 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
WO2007030697A3 (en) * 2005-09-07 2007-05-03 Braincells Inc Modulation of neurogenesis by hdac inhibition
EP1940379A2 (en) * 2005-09-30 2008-07-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methods for treatment of hemorrhagic shock and related disorders
EP1940379A4 (en) * 2005-09-30 2009-05-13 Jackson H M Found Military Med METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES
EP2018366A4 (en) * 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR
EP2018366A1 (en) * 2006-05-16 2009-01-28 McGILL UNIVERSITY Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
CN103819364A (zh) * 2014-01-24 2014-05-28 中南大学 N-烃酰基环内酰胺衍生物的一锅合成方法
CN103819364B (zh) * 2014-01-24 2015-12-02 中南大学 N-烃酰基环内酰胺衍生物的一锅合成方法
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Also Published As

Publication number Publication date
NO332749B1 (no) 2013-01-07
IL163909A0 (en) 2005-12-18
JP2014237669A (ja) 2014-12-18
JP5675071B2 (ja) 2015-02-25
CA2632078C (en) 2012-08-14
RU2394022C2 (ru) 2010-07-10
EP2266552A3 (en) 2011-03-02
RU2320331C2 (ru) 2008-03-27
JP2005525369A (ja) 2005-08-25
US20080119562A1 (en) 2008-05-22
RU2004133675A (ru) 2005-08-10
KR100868813B1 (ko) 2008-11-14
US20040072735A1 (en) 2004-04-15
US8067472B2 (en) 2011-11-29
US20040127522A1 (en) 2004-07-01
RU2010108448A (ru) 2011-09-20
NO20092714L (no) 2004-10-11
EP1487426A2 (en) 2004-12-22
NO20044112L (no) 2004-11-30
EP2082737A2 (en) 2009-07-29
EP2266552A2 (en) 2010-12-29
IL197582A (en) 2014-05-28
NZ550185A (en) 2008-10-31
AU2003213684C1 (en) 2008-10-23
EP2082737A3 (en) 2009-08-12
NZ567758A (en) 2009-07-31
JP4732693B2 (ja) 2011-07-27
MXPA04008577A (es) 2005-07-13
KR100892016B1 (ko) 2009-04-07
US7399787B2 (en) 2008-07-15
ZA200407942B (en) 2006-05-31
CN101259120B (zh) 2012-07-04
CA2632078A1 (en) 2003-09-18
EP1487426A4 (en) 2007-09-19
CN101259120A (zh) 2008-09-10
US20100210729A1 (en) 2010-08-19
KR20080041307A (ko) 2008-05-09
EP2322160A1 (en) 2011-05-18
JP5586896B2 (ja) 2014-09-10
AU2003213684B2 (en) 2007-04-26
RU2530648C2 (ru) 2014-10-10
US20120041067A1 (en) 2012-02-16
RU2007112879A (ru) 2008-10-20
US20080114069A1 (en) 2008-05-15
IL197582A0 (en) 2009-12-24
CN1720034A (zh) 2006-01-11
ZA200601757B (en) 2007-11-28
EP2082737B1 (en) 2014-12-31
NO329984B1 (no) 2011-01-31
ES2532607T3 (es) 2015-03-30
AU2003213684A1 (en) 2003-09-22
CN103393630A (zh) 2013-11-20
JP2010001302A (ja) 2010-01-07
HK1072362A1 (en) 2005-08-26
US20040127523A1 (en) 2004-07-01
KR20070057794A (ko) 2007-06-07
PL372239A1 (en) 2005-07-11
CA2671976A1 (en) 2003-09-18
US7732490B2 (en) 2010-06-08
CA2671976C (en) 2016-05-10
CA2478094A1 (en) 2003-09-18
BR0308250A (pt) 2005-01-11
JP2010006822A (ja) 2010-01-14
EP1487426B1 (en) 2012-08-22
WO2003075839A3 (en) 2003-12-31
IL163909A (en) 2010-12-30
CA2478094C (en) 2010-11-23
NZ535578A (en) 2008-03-28

Similar Documents

Publication Publication Date Title
CA2478094C (en) Methods of inducing terminal differentiation
US7375137B2 (en) Methods of treating cancer with HDAC inhibitors
US8101663B2 (en) Polymorphs of suberoylanilide hydroxamic acid
US20090012175A1 (en) Methods of treating cancer with HDAC inhibitors
Richon et al. Methods of treating Hodgkin's and non-Hodgkin's lymphoma
AU2007203525B2 (en) Methods of Inducing Terminal Differentiation
KR20050020760A (ko) 말단 분화의 유도 방법
NZ568678A (en) Methods of inducing terminal differentiation using suberoylanilide hydroxamic acid (SAHA)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003574115

Country of ref document: JP

Ref document number: 372239

Country of ref document: PL

Ref document number: PA/a/2004/008577

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047013883

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 163909

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2478094

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2721/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003213684

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 535578

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003711372

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/07942

Country of ref document: ZA

Ref document number: 200407942

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20038095890

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2004133675

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2003711372

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047013883

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2003213684

Country of ref document: AU